The most prescribed anti-inflamatory
drug Nimesulide was first developed by Helsinn
Healthcare and is marketed world-wide.
NImesulide is
available in the form of tablets (100 mg), granules for oral
suspension (100 mg), suppositories (200 mg) and gel (3%).
The
anti-inflammatory drug mechanism of Nimesulide should only be
prescribed as second line treatment. It provides the fast
onset of the analgesic action.
The rapid onset
of the analgesic action is crucial for
the patients with acute pain and also in
case of treatment with systemic NSAIDs
The harmonized indications in the EU are acute
pain, primary dysmenorrhoea. The dosage
of Nimesulide ought to be used is 100 mg twice daily, the duration
prescribed is 15 days to minimize the risk of hepatotoxicity.
The drug must be used under supervision by a
licensed physician in accordance with the approved indications.
Prescription of the Nimesulide must be based on assessment of the
patients’ characteristics and needs.
Nimesulide is contraindicated in children below 12 years and in
patients suffering from liver problems.
No comments:
Post a Comment